Impact of FDA Cuts on Device Department

This chapter discusses the recent cuts made by the FDA and their disproportionate impact on the device department compared to biotech. It highlights concerns over staffing shortages, delays in drug manufacturing inspections, and the potential implications for pharmaceutical companies and device reviews.